BOSTON, Mass. — Vektor Medical will present new clinical data from its VITAL-EP Registry at AF Symposium 2026, highlighting atrial fibrillation ablation results that demonstrate a fast, zero-fluoroscopy PVI-plus workflow and newly released atrial flutter capabilities.
The medical technology company said physician experiences and registry findings will be showcased during the conference, which runs February 5–8 in Boston, and will focus on how its vMap platform can improve procedural efficiency, support arrhythmia termination, and enable post-ablation non-inducibility.
A featured study titled “High Procedural Efficiency and Arrhythmia Non-Inducibility Using vMap for AF Ablation: Early Results from the Multicenter VITAL-EP Registry” will present real-world data showing how vMap supports low-fluoroscopy atrial fibrillation ablation workflows. According to Vektor Medical, the results demonstrate highly efficient procedures, frequent arrhythmia termination during ablation, high rates of post-ablation non-inducibility, and a strong safety profile across paroxysmal, persistent, and longstanding persistent atrial fibrillation cases.
Registry findings showed a median PVI-plus procedure time of approximately 70 minutes, a median fluoroscopy time of zero minutes, and a median mapping time of less than 10 minutes. The multicenter registry reflects a range of clinical sites, operators, and ablation approaches.
“These early results show that vMap can meaningfully enhance procedural efficiency while maintaining an exceptionally low fluoroscopy footprint,” said Saumil Oza, M.D. “For patients, this means safer procedures. For electrophysiologists, it means faster mapping and a clearer path to confident decision-making in the lab.”
Rob Krummen, chief executive officer of Vektor Medical, said the early registry data demonstrate the platform’s real-world impact on ablation strategies. He added that extending non-invasive ECG-based analysis to both atrial fibrillation and atrial flutter gives electrophysiologists clearer insight into arrhythmias and supports more confident, patient-centered treatment planning.
The company will also highlight its newly released atrial flutter workflow, which enables non-invasive analysis to distinguish between typical and atypical atrial flutter using a standard 12-lead ECG. The update allows clinicians to evaluate both atrial fibrillation and atrial flutter on a single non-invasive mapping platform, supporting more comprehensive arrhythmia assessment and treatment planning.
As part of the conference program, Dr. Sei Iwai, section chief of cardiac electrophysiology at Westchester Medical Center Health Network, is scheduled to deliver a spotlight session on February 5 at 8:30 a.m. The presentation will review clinical experiences using vMap to non-invasively localize patient-specific atrial fibrillation drivers and guide ablation strategies beyond pulmonary vein isolation. (Source: IANS)
